CRISPR Therapeutics AG (CRSP) Receivables - Other (2016 - 2024)

CRISPR Therapeutics AG (CRSP) has 9 years of Receivables - Other data on file, last reported at $2.1 million in Q4 2024.

• For the quarter ending Q4 2024, Receivables - Other fell 67.69% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2024 stood at $2.1 million (down 67.69% YoY), and the FY2024 full-year result was $2.1 million, down 67.69% from the prior year.
• Receivables - Other fell to $2.1 million in Q4 2024, from $6.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $25.0 million in Q1 2020 to a low of $2.1 million in Q4 2024.
• A 5-year average of $14.2 million and a median of $11.0 million in 2020 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other soared 7688.16% in 2020 and sank 67.69% in 2024, its largest moves.
• Tracing CRSP's Receivables - Other over 5 years: stood at $10.7 million in 2020, then dropped by 21.5% to $8.4 million in 2021, then jumped by 33.33% to $11.2 million in 2022, then tumbled by 41.96% to $6.5 million in 2023, then slumped by 67.69% to $2.1 million in 2024.
• Business Quant data shows CRSP's Receivables - Other at $2.1 million in Q4 2024, $6.5 million in Q4 2023, and $11.2 million in Q4 2022.